Brainstorm Cell Therapeutics Inc.

2.80+0.0300+1.08%Vol 50.22K1Y Perf -30.40%
Jun 28th, 2022 16:00 DELAYED
BID2.76 ASK2.94
Open2.74 Previous Close2.77
Pre-Market- After-Market-
 - -  - -%
Target Price
11.00 
Analyst Rating
Hold 3.00
Potential %
292.86 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
8.29 
Earnings Rating
Strong Buy
Market Cap102.16M 
Earnings Date
4th Aug 2022
Alpha0.01 Standard Deviation0.21
Beta0.05 

Today's Price Range

2.692.82

52W Range

2.654.46

5 Year PE Ratio Range

-10.70-6.40

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Week
-5.46%
1 Month
-7.05%
3 Months
-14.24%
6 Months
-29.87%
1 Year
-30.40%
3 Years
-29.87%
5 Years
-34.20%
10 Years
-32.60%

TickerPriceChg.Chg.%
BCLI2.800.03001.08
AAPL137.44-4.2200-2.98
GOOG2 251.43-81.0200-3.47
MSFT256.48-8.4100-3.17
XOM91.502.47002.77
WFC40.18-0.0600-0.15
JNJ176.94-5.1800-2.84
FB196.640.99000.51
GE65.88-0.8300-1.24
JPM115.82-0.5600-0.48
Earnings HistoryEstimateReportedSurprise %
Q01 2022-0.13-0.15-15.38
Q04 2021-0.20-0.1715.00
Q03 2021-0.21-0.1528.57
Q02 2021-0.20-0.1715.00
Q01 2021-0.27-0.1929.63
Q04 2020-0.48-0.3722.92
Q03 2020-0.24-0.1441.67
Q02 2020-0.24-0.25-4.17
Earnings Per EndEstimateRevision %Trend
6/2022 QR-0.1548.28Positive
9/2022 QR-0.1546.43Positive
12/2022 FY-0.6146.02Positive
12/2023 FY-0.6542.48Positive
Next Report Date4th Aug 2022
Estimated EPS Next Report-0.15
Estimates Count2
EPS Growth Next 5 Years %-
Volume Overview
Volume50.22K
Shares Outstanding36.49K
Shares Float33.72M
Trades Count418
Dollar Volume138.96K
Avg. Volume58.13K
Avg. Weekly Volume58.31K
Avg. Monthly Volume52.23K
Avg. Quarterly Volume63.86K

Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI) stock closed at 2.77 per share at the end of the most recent trading day (a 1.84% change compared to the prior day closing price) with a volume of 51.04K shares and market capitalization of 102.16M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 40 people. Brainstorm Cell Therapeutics Inc. CEO is Chaim Lebovits.

The one-year performance of Brainstorm Cell Therapeutics Inc. stock is -30.4%, while year-to-date (YTD) performance is -30.75%. BCLI stock has a five-year performance of -34.2%. Its 52-week range is between 2.65 and 4.46, which gives BCLI stock a 52-week price range ratio of 8.29%

Brainstorm Cell Therapeutics Inc. currently has a PE ratio of -4.30, a price-to-book (PB) ratio of 6.85, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -64.63%, a ROC of -73.83% and a ROE of -95.15%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Brainstorm Cell Therapeutics Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.15 for the next earnings report. Brainstorm Cell Therapeutics Inc.’s next earnings report date is 04th Aug 2022.

The consensus rating of Wall Street analysts for Brainstorm Cell Therapeutics Inc. is Hold (3), with a target price of $11, which is +292.86% compared to the current price. The earnings rating for Brainstorm Cell Therapeutics Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Brainstorm Cell Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Brainstorm Cell Therapeutics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 28.99, ATR14 : 0.14, CCI20 : -152.28, Chaikin Money Flow : -0.22, MACD : -0.04, Money Flow Index : 14.60, ROC : -7.36, RSI : 41.79, STOCH (14,3) : 21.21, STOCH RSI : 0.34, UO : 47.76, Williams %R : -78.79), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Brainstorm Cell Therapeutics Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
1 (100.00 %)
1 (100.00 %)
1 (100.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingHold
3.00
Hold
3.00
Hold
3.00

Brainstorm Cell Therapeutics Inc.

Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases.

CEO: Chaim Lebovits

Telephone: +1 201 488-0460

Address: 1325 Avenue of Americas, New York 10019, NY, US

Number of employees: 40

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

60%40%

Bearish Bullish

70%30%

Bearish Bullish

56%44%

TipRanks News for BCLI

Wed, 05 Jan 2022 09:13 GMT Brainstorm Cell Therapeutics (BCLI) Gets a Hold Rating from Dawson James

- TipRanks. All rights reserved.

News

Stocktwits